Sarepta Therapeutics Inc. shares surged in the extended session Thursday after the genetic medicine company said the Food and Drug Administration approved its muscular dystrophy treatment. Sarepta shares rallied 23% after hours before being halted, and were last up 28% after being unhalted. Shares closed the regular session down 1% at $100.47. The company said the FDA approved Vyondys 53 for the treatment of Duchenne muscular dystrophy. The company said Vyondys 53 will be priced similarly to its other DMD treatment Exondys 51, which has not had a price increase since 2016. Back in August, shares dropped after the FDA said it could not approve the drug on concerns about kidney toxicity. At Thursday's close, Sarepta shares were down 8% for the year.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.



More...